drugset / Trial / NCT00972660

Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease

NCT00972660

RandomizedParallel-groupOpen-labelTreatment

Summary

Study Design: Treatment, Randomized, Open Label, Parallel Assignment,Safety/Efficacy Study. The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSC) expanded ex-vivo infusion for the treatment of patients who have developed a newly diagnosed extensive or refractory chronic graft versus host disease (chronic GVHD) to the usual therapeutic measures.

Timeline

Start
2009-09
Primary completion
2015-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal stem cell Cell therapy 2e+06 cells/kg Intravenous
Comparator Cyclosporine Peptide
Comparator Methotrexate Small molecule
Comparator Mycophenolate Mofetil Small molecule
Comparator Prednisone Other / unclassified 1 mg/kg
Comparator Tacrolimus Small molecule